{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T15:21:31Z","timestamp":1772119291362,"version":"3.50.1"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2017,12,8]],"date-time":"2017-12-08T00:00:00Z","timestamp":1512691200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2018,2]]},"DOI":"10.1007\/s00280-017-3486-3","type":"journal-article","created":{"date-parts":[[2017,12,8]],"date-time":"2017-12-08T07:02:39Z","timestamp":1512716559000},"page":"325-332","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Model based analysis of the heterogeneity in the tumour size dynamics differentiates vemurafenib, dabrafenib and trametinib in metastatic melanoma"],"prefix":"10.1007","volume":"81","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9683-1903","authenticated-orcid":false,"given":"Hitesh B.","family":"Mistry","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Orrell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raluca","family":"Eftimie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,12,8]]},"reference":[{"key":"3486_CR1","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1038\/nrc3971","volume":"15","author":"DP Tabassum","year":"2015","unstructured":"Tabassum DP, Polyak K (2015) Tumorigenesis: it takes a village. Nat Rev Cancer 15:473\u2013483. \n                        https:\/\/doi.org\/10.1038\/nrc3971","journal-title":"Nat Rev Cancer"},{"key":"3486_CR2","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/BF00047691","volume":"3","author":"GL Nicolson","year":"1984","unstructured":"Nicolson GL (1984) Generation of phenotypic diversity and progression in metastatic tumor cells. Cancer Metastasis Rev 3:25\u201342","journal-title":"Cancer Metastasis Rev"},{"key":"3486_CR3","first-page":"2259","volume":"44","author":"GH Heppner","year":"1984","unstructured":"Heppner GH (1984) Tumor heterogeneity. Cancer Res 44:2259\u20132265","journal-title":"Cancer Res"},{"key":"3486_CR4","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1200\/JCO.1986.4.2.244","volume":"4","author":"DL Dexter","year":"1986","unstructured":"Dexter DL, Leith JT (1986) Tumor heterogeneity and drug resistance. J Clin Oncol Off J Am Soc Clin Oncol 4:244\u2013257","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"3486_CR5","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer Oxf Engl 1990 45:228\u2013247. \n                        https:\/\/doi.org\/10.1016\/j.ejca.2008.10.026","journal-title":"Eur J Cancer Oxf Engl 1990"},{"key":"3486_CR6","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1038\/nature09454","volume":"467","author":"G Bollag","year":"2010","unstructured":"Bollag G, Hirth P, Tsai J et al (2010) Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature 467:596\u2013599. \n                        https:\/\/doi.org\/10.1038\/nature09454","journal-title":"Nature"},{"key":"3486_CR7","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1158\/1541-7786.MCR-07-2001","volume":"6","author":"E Sala","year":"2008","unstructured":"Sala E, Mologni L, Truffa S et al (2008) BRAF silencing by short hairpin RNA or chemical blockade by PLX4032 leads to different responses in melanoma and thyroid carcinoma cells. Mol Cancer Res 6:751\u2013759. \n                        https:\/\/doi.org\/10.1158\/1541-7786.MCR-07-2001","journal-title":"Mol Cancer Res"},{"key":"3486_CR8","doi-asserted-by":"publisher","first-page":"B88","DOI":"10.1158\/1535-7163.TARG-09-B88","volume":"8","author":"S Laquerre","year":"2009","unstructured":"Laquerre S, Arnone M, Moss K et al (2009) Abstract B88: a selective Raf kinase inhibitor induces cell death and tumor regression of human cancer cell lines encoding B-RafV600E mutation. Mol Cancer Ther 8:B88\u2013B88. \n                        https:\/\/doi.org\/10.1158\/1535-7163.TARG-09-B88","journal-title":"Mol Cancer Ther"},{"key":"3486_CR9","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1158\/1078-0432.CCR-10-2200","volume":"17","author":"AG Gilmartin","year":"2011","unstructured":"Gilmartin AG, Bleam MR, Groy A et al (2011) GSK1120212 (JTP-74057) is an inhibitor of MEK activity and activation with favorable pharmacokinetic properties for sustained in vivo pathway inhibition. Clin Cancer Res Off J Am Assoc Cancer Res 17:989\u20131000. \n                        https:\/\/doi.org\/10.1158\/1078-0432.CCR-10-2200","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"3486_CR10","first-page":"96","volume":"38","author":"J McCain","year":"2013","unstructured":"McCain J (2013) The MAPK (ERK) pathway. Pharm Ther 38:96\u2013108","journal-title":"Pharm Ther"},{"key":"3486_CR11","doi-asserted-by":"publisher","first-page":"2507","DOI":"10.1056\/NEJMoa1103782","volume":"364","author":"PB Chapman","year":"2011","unstructured":"Chapman PB, Hauschild A, Robert C et al (2011) Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 364:2507\u20132516. \n                        https:\/\/doi.org\/10.1056\/NEJMoa1103782","journal-title":"N Engl J Med"},{"key":"3486_CR12","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1016\/S0140-6736(12)60868-X","volume":"380","author":"A Hauschild","year":"2012","unstructured":"Hauschild A, Grob J-J, Demidov LV et al (2012) Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet Lond Engl 380:358\u2013365. \n                        https:\/\/doi.org\/10.1016\/S0140-6736(12)60868-X","journal-title":"Lancet Lond Engl"},{"key":"3486_CR13","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1056\/NEJMoa1203421","volume":"367","author":"KT Flaherty","year":"2012","unstructured":"Flaherty KT, Robert C, Hersey P et al (2012) Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med 367:107\u2013114. \n                        https:\/\/doi.org\/10.1056\/NEJMoa1203421","journal-title":"N Engl J Med"},{"key":"3486_CR14","first-page":"988","volume":"76","author":"VP Collins","year":"1956","unstructured":"Collins VP, Loeffler RK, Tivey H (1956) Observations on growth rates of human tumors. Am J Roentgenol Radium Ther Nucl Med 76:988\u20131000","journal-title":"Am J Roentgenol Radium Ther Nucl Med"},{"key":"3486_CR15","first-page":"841","volume":"16","author":"WV Mayneord","year":"1932","unstructured":"Mayneord WV (1932) On a law of growth of Jensen\u2019s rat sarcoma. Am J Cancer 16:841\u2013846","journal-title":"Am J Cancer"},{"key":"3486_CR16","doi-asserted-by":"publisher","first-page":"13545","DOI":"10.1038\/srep13545","volume":"5","author":"S Checkley","year":"2015","unstructured":"Checkley S, MacCallum L, Yates J et al (2015) Bridging the gap between in vitro and in vivo: dose and schedule predictions for the ATR inhibitor AZD6738. Sci Rep 5:13545. \n                        https:\/\/doi.org\/10.1038\/srep13545","journal-title":"Sci Rep"},{"key":"3486_CR17","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1016\/j.molonc.2014.06.005","volume":"8","author":"RA Burrell","year":"2014","unstructured":"Burrell RA, Swanton C (2014) Tumour heterogeneity and the evolution of polyclonal drug resistance. Mol Oncol 8:1095\u20131111. \n                        https:\/\/doi.org\/10.1016\/j.molonc.2014.06.005","journal-title":"Mol Oncol"},{"key":"3486_CR18","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1038\/bjc.2012.581","volume":"108","author":"R Fisher","year":"2013","unstructured":"Fisher R, Pusztai L, Swanton C (2013) Cancer heterogeneity: implications for targeted therapeutics. Br J Cancer 108:479\u2013485. \n                        https:\/\/doi.org\/10.1038\/bjc.2012.581","journal-title":"Br J Cancer"},{"key":"3486_CR19","doi-asserted-by":"publisher","first-page":"2486","DOI":"10.1016\/j.ejca.2013.03.027","volume":"49","author":"CS Kessel van","year":"2013","unstructured":"van Kessel CS, Samim M, Koopman M et al (2013) Radiological heterogeneity in response to chemotherapy is associated with poor survival in patients with colorectal liver metastases. Eur J Cancer Oxf Engl 1990 49:2486\u20132493. \n                        https:\/\/doi.org\/10.1016\/j.ejca.2013.03.027","journal-title":"Eur J Cancer Oxf Engl 1990"},{"key":"3486_CR20","doi-asserted-by":"publisher","first-page":"e371","DOI":"10.1016\/S1470-2045(14)70072-5","volume":"15","author":"AM Menzies","year":"2014","unstructured":"Menzies AM, Long GV (2014) Systemic treatment for BRAF-mutant melanoma: where do we go next? Lancet Oncol 15:e371\u2013e381. doi: \n                        https:\/\/doi.org\/10.1016\/S1470-2045(14)70072-5","journal-title":"Lancet Oncol"},{"key":"3486_CR21","unstructured":"Optogenetically controlled RAF to characterize BRAF and CRAF protein kinase inhibitors: scientific Reports. \n                        http:\/\/www.nature.com\/articles\/srep23713\n                        \n                    . Accessed 23 May 2016"},{"key":"3486_CR22","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1093\/annonc\/mdt587","volume":"25","author":"B Schilling","year":"2014","unstructured":"Schilling B, Sondermann W, Zhao F et al (2014) Differential influence of vemurafenib and dabrafenib on patients\u2019 lymphocytes despite similar clinical efficacy in melanoma. Ann Oncol Off J Eur Soc Med Oncol ESMO 25:747\u2013753. \n                        https:\/\/doi.org\/10.1093\/annonc\/mdt587","journal-title":"Ann Oncol Off J Eur Soc Med Oncol ESMO"},{"key":"3486_CR23","doi-asserted-by":"publisher","first-page":"391","DOI":"10.2147\/DDDT.S38998","volume":"6","author":"AM Menzies","year":"2012","unstructured":"Menzies AM, Long GV, Murali R (2012) Dabrafenib and its potential for the treatment of metastatic melanoma. Drug Des Devel Ther 6:391\u2013405. \n                        https:\/\/doi.org\/10.2147\/DDDT.S38998","journal-title":"Drug Des Devel Ther"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-017-3486-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-017-3486-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-017-3486-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,1,22]],"date-time":"2018-01-22T07:21:13Z","timestamp":1516605673000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-017-3486-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12,8]]},"references-count":23,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,2]]}},"alternative-id":["3486"],"URL":"https:\/\/doi.org\/10.1007\/s00280-017-3486-3","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/103366","asserted-by":"object"}]},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,12,8]]}}}